🇺🇸 FDA
Pipeline program

Pluvicto 1 000 MBq/mL solution for injection/infusion

EORTC-2361-GUCG

Phase 2 small_molecule active

Quick answer

Pluvicto 1 000 MBq/mL solution for injection/infusion for Clear Cell Renal Cell Carcinoma (ccRCC) is a Phase 2 program (small_molecule) at Cancer Prevention Pharma (Ireland) Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Cancer Prevention Pharma (Ireland) Limited
Indication
Clear Cell Renal Cell Carcinoma (ccRCC)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials